Purnima Singh

Associate Professor

The University of Alabama

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Purnima Singh is an Associate Professor at the University of Alabama at Birmingham, United States. Her research focuses on the long-term health effects of cancer treatments in childhood survivors, specifically examining genetic mutations, therapy-related myeloid neoplasms, and cardiomyopathy. She has contributed to significant studies, including those on clonal hematopoiesis and its implications for childhood cancer survivors.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Noha Sharafeldin

Assistant Professor

The University of Alabama

UNITED STATES

View details

Tarek Magdy

Assistant Professor

UNITED STATES

View details

Wanding Zhou

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES

View details

Piroska Szabó

Van Andel Institute

UNITED STATES

View details

Wendy Landier

The University of Alabama

UNITED STATES

View details

David Crossman

Assistant Professor/Bioinformatics Director

The University of Alabama

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Purnima Singh

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study

Clonal hematopoiesis and subsequent venous thromboembolism among survivors of autologous transplantation for lymphoma

DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children’s Oncology Group and the Childhood Cancer Survivor Study

Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

Standard PREanalytical Code Version 4.0

Gene-Level Analysis of Anthracycline-Induced Cardiomyopathy in Cancer Survivors

Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy

Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report

Genome-Wide Association Study Identifies <i>ROBO2</i> as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors

Genome-wide variants and polygenic risk scores for cognitive impairment following blood or marrow transplantation

Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial

EHMT2 suppresses the variation of transcriptional switches in the mouse embryo.

Prenatal correction of IGF2 to rescue the growth phenotypes in mouse models of Beckwith-Wiedemann and Silver-Russell syndromes.

Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.

Association of GSTM1 null variant with anthracycline‐related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report

Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy.

Collaborators (6)

Noha Sharafeldin

Tarek Magdy

Wanding Zhou

Piroska Szabó

Wendy Landier

David Crossman

Make your next move.